Result of AGM

RNS Number : 9918F

Oxford Biomedica PLC

23 May 2017

 

Oxford BioMedica Annual General Meeting

London, UK - 23 May 2017: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, announces today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London.

In accordance with Listing Rule 9.6.18 the following resolutions are those which were passed at the meeting concerning special business:

·      Resolution 7: to authorise the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares;

·      Resolution 8: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares in connection with an acquisition or specified capital investment; and

·      Resolution 9: to permit the Directors to convene general meetings (other than annual general meetings) on not less than 14 days' notice.

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Group's website at www.oxfordbiomedica.co.uk.

Certified copies of the document setting out the above resolutions passed at the 2017 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: http://www.morningstar.co.uk/uk/NSM.

The results of the proxy voting in advance of the meeting are shown below.  On the Record Date (19 May 2017) there were 3,088,326,065 1p ordinary shares in issue, each carrying one vote per share.

Resolution	Votes For	Votes at Chairman's Discretion	Votes at other proxy Discretion	Votes Against	Votes Withheld	Total votes cast	Result
Ordinary resolutions
1	1,888,465,188	802,799	6,958,793	604,970	398,641	1,897,230,391	Passed
2	1,601,919,465	928,694	6,958,793	4,701,911	282,721,528	1,897,230,391	Passed
3	1,880,264,095	868,254	6,958,793	1,126,450	8,012,799	1,897,230,391	Passed
4	1,880,712,558	872,425	6,958,793	664,300	8,022,315	1,897,230,391	Passed
5	1,813,674,842	880,635	6,958,793	75,322,036	394,085	1,897,230,391	Passed
6	1,887,924,882	925,661	6,958,793	857,070	563,985	1,897,230,391	Passed
Special resolutions
7	1,774,042,262	1,002,090	6,958,793	1,619,809	113,607,437	1,897,230,391	Passed
8	1,887,104,129	1,002,090	6,958,793	1,557,942	607,437	1,897,230,391	Passed
9	1,879,803,796	1,001,125	6,958,793	9,042,530	424,147	1,897,230,391	Passed

- Ends -

For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer	Tel: [phone]
Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton	Tel: [phone]

Notes for editors

About Oxford BioMedica^®

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector^®) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.

 

END

 

 

RAGSEFFDDFWSESI